Celon Pharma SA CLN

GPW · Poland · Health Technology

PLN 18.700.00 (0.00%)

Market closed· Oct 1, 2026, 3:00 PM UTC· PLN · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Celon Pharma SA CLN

GPW · Poland · Health Technology

PLN 18.700.00 (0.00%)

Market closed· Oct 1, 2026, 3:00 PM UTC· PLN · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-7.88% · 6MFull-screen chart

Open PLN 18.70High PLN 18.90Low PLN 18.00Close PLN 18.70Volume 26.01K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: PLN 18.70
Day range: PLN 18.00 – PLN 18.90
52-week range: PLN 18.00 – PLN 23.50
Volume: 26.01K
Market cap: PLN 1.01B
P/E (TTM): 9.2
Next earnings date: 2026-11-18
Avg. volume (1Y): 13.10K

Performance

1 week

-5.56%

1 month

-16.14%

3 months

-5.46%

6 months

-7.88%

Year to date

-8.33%

1 year

-15.38%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Poland
Exchange: GPW
Shares outstanding: 53.91M
Employees: 562
ISIN: PLCLNPH00015
Beta: 0.70

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceOct 08, 2025

FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial

FDA clears path for Phase 3 testing following positive Type B meetingRegulatory alignment confirms preclinical data sufficient for pivotal initiationPhase 3 to include two 28-day trials and a 12-month safety extensionCPL’36 demonstrated strong efficacy and safety in prior Phase 2 studyProgram expansion planned into additional CNS indications, including Parkinson’s disease WARSAW, Poland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (WSE: CLN) announced today it has secured a key regulator

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.